Clinical Trial Update: Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) [Phase 2]

View source ↗

Summary

A Phase 2 trial of Edecesertib for Cutaneous Lupus Erythematosus has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus

Drugs mentioned

• Edecesertib (Edecesertib)

Snippet

Sponsor: Gilead Sciences | Conditions: Cutaneous Lupus Erythematosus (CLE) | Phase 2 | Status: TERMINATED